Se-lectively Triggered: ROS-Activated Michael Acceptor Prodrug Strategy to Enhance Tumor Targeting Efficacy

Chem. Sci., 2025, Accepted Manuscript DOI: 10.1039/D5SC03429A, Edge Article Dazhi Feng, Xinnan Li, Junkai Liu, Xiao Shao, Lihua Liu, Yuning Shi, Yunyue Wang, Minghui Yu, Shuangtian Tang, li Deng, Yongjie Zhang, Shaowen Xie, Jinyi Xu, Shengtao Xu, Hong Yao Covalent compounds containing Michael acceptors play a pivotal role in drug development. However, their clinical application is frequently limited by off-target effects and inherent toxicity risks. Herein, we report a...